Company intelligence / Profile preview
Pharmaleads
Paris, Île-de-France, Francepharmaleads.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Pharmaleads develops non-opiate, small molecule drugs for the management of acute and chronic severe pain using its proprietary DENKI technology. The company’s approach leverages dual enkephalinase inhibitors to increase endogenous enkephalins for improved analgesia without opioid side effects. Its pipeline includes candidates targeting neuropathic, ocular, post-surgical pain, migraine disorders, and neuralgia. At least two products are in clinical or preclinical development; detailed recent clinical results are not specified in public sources.
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- Small molecules (specifically Dual ENKephalinase Inhibitors - DENKIs)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Pharmaleads.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharmaleads.